BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fond G, Godin O, Boyer L, Berna F, Andrianarisoa M, Coulon N, Brunel L, Bulzacka E, Aouizerate B, Capdevielle D, Chereau I, D'Amato T, Dubertret C, Dubreucq J, Faget C, Leignier S, Lançon C, Mallet J, Misdrahi D, Passerieux C, Rey R, Schandrin A, Urbach M, Vidailhet P, Llorca PM, Schürhoff F, Leboyer M; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group. Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort. Eur Arch Psychiatry Clin Neurosci 2019;269:985-92. [PMID: 29808267 DOI: 10.1007/s00406-018-0908-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Rantala MJ, Luoto S, Borráz-León JI, Krams I. Schizophrenia: the new etiological synthesis. Neurosci Biobehav Rev 2022;:104894. [PMID: 36181926 DOI: 10.1016/j.neubiorev.2022.104894] [Reference Citation Analysis]
2 Osborne LM, Payne JL, Sherer ML, Sabunciyan S. Altered extracellular mRNA communication in postpartum depression is associated with decreased autophagy. Mol Psychiatry 2022. [PMID: 36138128 DOI: 10.1038/s41380-022-01794-2] [Reference Citation Analysis]
3 Yee JY, Chow SQ, Lim K, Goh W, Sng J, Lee T, Lee J. Haptoglobin in ultra-high risk of psychosis – Findings from the longitudinal youth at risk study (LYRIKS). Brain, Behavior, & Immunity - Health 2022;23:100481. [DOI: 10.1016/j.bbih.2022.100481] [Reference Citation Analysis]
4 Chumakov E, Dorofeikova M, Tsyrenova K, Petrova N. A Cross-Sectional Study on Associations Between BDNF, CRP, IL-6 and Clinical Symptoms, Cognitive and Personal Performance in Patients With Paranoid Schizophrenia. Front Psychiatry 2022;13:943869. [PMID: 35873262 DOI: 10.3389/fpsyt.2022.943869] [Reference Citation Analysis]
5 Veselinović T, Neuner I. Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia. CNS Drugs 2022. [PMID: 35831706 DOI: 10.1007/s40263-022-00935-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Lestra V, Romeo B, Martelli C, Benyamina A, Hamdani N. Could CRP be a differential biomarker of illness stages in schizophrenia? A systematic review and meta-analysis. Schizophr Res 2022;246:175-86. [PMID: 35785580 DOI: 10.1016/j.schres.2022.06.026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Domínguez-Avila JA, Salazar-López NJ, Montiel-Herrera M, Martínez-Martínez A, Villegas-Ochoa MA, González-Aguilar GA. Phenolic compounds can induce systemic and central immunomodulation, which result in a neuroprotective effect. J Food Biochem 2022;:e14260. [PMID: 35633197 DOI: 10.1111/jfbc.14260] [Reference Citation Analysis]
8 Karakayali E, Kocamaz E, Alpay Ş, Önal T, Öztatlici M, Duruşma R, Özel HF, Mete M, Kutlu N, Tuğlu Mİ. Effect of Probiotics on the Traumatic Brain Injury. forbes 2022;3:59-67. [DOI: 10.4274/forbes.galenos.2022.48658] [Reference Citation Analysis]
9 Subbanna M, Shivakumar V, Bhalerao G, Varambally S, Venkatasubramanian G, Debnath M. Variants of Th17 pathway-related genes influence brain morphometric changes and the risk of schizophrenia through epistatic interactions. Psychiatr Genet 2022:YPG. [PMID: 35353801 DOI: 10.1097/YPG.0000000000000315] [Reference Citation Analysis]
10 Vallée A. Neuroinflammation in Schizophrenia: The Key Role of the WNT/β-Catenin Pathway. Int J Mol Sci 2022;23:2810. [PMID: 35269952 DOI: 10.3390/ijms23052810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Labonté C, Zhand N, Park A, Harvey PD. Complete blood count inflammatory markers in treatment-resistant schizophrenia: Evidence of association between treatment responsiveness and levels of inflammation. Psychiatry Res 2021;308:114382. [PMID: 34995832 DOI: 10.1016/j.psychres.2021.114382] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Ullah I, Awan HA, Aamir A, Diwan MN, de Filippis R, Awan S, Irfan M, Fornaro M, Ventriglio A, Vellante F, Pettorruso M, Martinotti G, Di Giannantonio M, De Berardis D. Role and Perspectives of Inflammation and C-Reactive Protein (CRP) in Psychosis: An Economic and Widespread Tool for Assessing the Disease. Int J Mol Sci 2021;22:13032. [PMID: 34884840 DOI: 10.3390/ijms222313032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
13 Maślińska M, Trędzbor B, Krzystanek M. Dysbiosis, gut-blood barrier rupture and autoimmune response in rheumatoid arthritis and schizophrenia. Reumatologia 2021;59:180-7. [PMID: 34538945 DOI: 10.5114/reum.2021.107588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Javelot H, Gitahy Falcao Faria C, Vandenberghe F, Dizet S, Langrée B, Le Maout M, Straczek C, Egron A, Erb A, Sujol G, Yrondi A, Weibel S, Vincent PD, Meyer G, Hingray C. Clinical Pharmacy in Psychiatry: Towards Promoting Clinical Expertise in Psychopharmacology. Pharmacy (Basel) 2021;9:146. [PMID: 34449724 DOI: 10.3390/pharmacy9030146] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Ľupták M, Michaličková D, Fišar Z, Kitzlerová E, Hroudová J. Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets. World J Psychiatr 2021; 11(7): 277-296 [PMID: 34327122 DOI: 10.5498/wjp.v11.i7.277] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
16 Spangaro M, Martini F, Bechi M, Buonocore M, Agostoni G, Cocchi F, Sapienza J, Bosia M, Cavallaro R. Longitudinal course of cognition in schizophrenia: Does treatment resistance play a role? J Psychiatr Res 2021;141:346-52. [PMID: 34304039 DOI: 10.1016/j.jpsychires.2021.07.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
17 Cathomas F, Klaus F, Guetter K, Chung HK, Raja Beharelle A, Spiller TR, Schlegel R, Seifritz E, Hartmann-Riemer MN, Tobler PN, Kaiser S. Increased random exploration in schizophrenia is associated with inflammation. NPJ Schizophr 2021;7:6. [PMID: 33536449 DOI: 10.1038/s41537-020-00133-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
18 Leboyer M, Godin O, Terro E, Boukouaci W, Lu CL, Andre M, Aouizerate B, Berna F, Barau C, Capdevielle D, Clauss-Kobayashi J, Chereau I, D Amato T, Dubertret C, Dubreucq J, Fond G, Laouamri H, Leignier S, Lancon C, Llorca PM, Mallet J, Le Corvoisier P, Misdrahi D, Passerieux C, Rey R, Pignon B, Urbach M, Szoke A, Schürhoff F, Tamouza R; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Groups . Immune Signatures of Treatment-Resistant Schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) Study. Schizophr Bull Open 2021;2:sgab012. [PMID: 34901861 DOI: 10.1093/schizbullopen/sgab012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
19 Kowal C, Peyre H, Amad A, Pelissolo A, Leboyer M, Schürhoff F, Pignon B. Psychotic, Mood, and Anxiety Disorders and Venous Thromboembolism: A Systematic Review and Meta-Analysis. Psychosom Med 2020;82:838-49. [PMID: 32947580 DOI: 10.1097/PSY.0000000000000863] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
20 Dey P. Targeting gut barrier dysfunction with phytotherapies: Effective strategy against chronic diseases. Pharmacol Res 2020;161:105135. [PMID: 32814166 DOI: 10.1016/j.phrs.2020.105135] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
21 Fond GB, Lagier JC, Honore S, Lancon C, Korchia T, Sunhary De Verville PL, Llorca PM, Auquier P, Guedj E, Boyer L. Microbiota-Orientated Treatments for Major Depression and Schizophrenia. Nutrients 2020;12:E1024. [PMID: 32276499 DOI: 10.3390/nu12041024] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
22 Fond G, Lançon C, Korchia T, Auquier P, Boyer L. The Role of Inflammation in the Treatment of Schizophrenia. Front Psychiatry 2020;11:160. [PMID: 32256401 DOI: 10.3389/fpsyt.2020.00160] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 21.5] [Reference Citation Analysis]
23 Holland JF, Khandaker GM, Dauvermann MR, Morris D, Zammit S, Donohoe G. Effects of early life adversity on immune function and cognitive performance: results from the ALSPAC cohort. Soc Psychiatry Psychiatr Epidemiol 2020;55:723-33. [DOI: 10.1007/s00127-019-01813-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
24 Panaccione I, Di Cesare G, Sani G, Ducci G. Treatment of Childhood Trauma: Pharmacological Approach. Childhood Trauma in Mental Disorders 2020. [DOI: 10.1007/978-3-030-49414-8_20] [Reference Citation Analysis]
25 Cavieres A, Campos-Estrada C, Moya Y, Maldonado R, González-Vargas R, Bustamante ML, Moya PR. Lack of Association between the IL6R Gene Asp358Ala Variant (rs2228145), IL-6 Plasma Levels, and Treatment Resistance in Chilean Schizophrenic Patients Treated with Clozapine. Schizophr Res Treatment 2019;2019:5601249. [PMID: 31341681 DOI: 10.1155/2019/5601249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
26 Severance EG, Yolken RH. Deciphering microbiome and neuroactive immune gene interactions in schizophrenia. Neurobiol Dis 2020;135:104331. [PMID: 30471416 DOI: 10.1016/j.nbd.2018.11.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
27 Sommer O, Aug RL, Schmidt AJ, Heiser P, Schulz E, Vedder H, Clement HW. Hydrogen Sulfide Affects Radical Formation in the Hippocampus of LPS Treated Rats and the Effect of Antipsychotics on Hydrogen Sulfide Forming Enzymes in Human Cell Lines. Front Psychiatry 2018;9:501. [PMID: 30386265 DOI: 10.3389/fpsyt.2018.00501] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
28 Zakrocka I, Targowska-Duda KM, Wnorowski A, Kocki T, Jóźwiak K, Turski WA. Influence of Cyclooxygenase-2 Inhibitors on Kynurenic Acid Production in Rat Brain in Vitro. Neurotox Res 2019;35:244-54. [PMID: 30178287 DOI: 10.1007/s12640-018-9952-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]